ESMO 2021: Alternative treatment schedule for ipilimumab plus nivolumab in first-line treatment of advanced RCC (PRISM)

By |2021-09-21T07:54:24+00:0021 Sep 2021|Drug treatments|

Ipilimumab plus nivolumab is a standard first-line treatment for patients [...]